The role of Serine Proteases and Serine Protease Inhibitors in the migration of Gonadotropin-Releasing Hormone neurons
BMC Developmental Biology volume 2, Article number: 1 (2002)
Mechanisms regulating neuronal migration during development remain largely undefined. Extracellular matrix cues, target site released factors, and components of the migratory neurons themselves are likely all coordinated in time and space directing neurons to their appropriate locations. We have studied the effects of proteases and their inhibitors on the extracellular matrix and the consequences to the migration of gonadotropin releasing hormone (GnRH) neurons in the embryonic chick. Chick GnRH neurons differentiate in the olfactory epithelium, migrate along the olfactory nerve and enter the forebrain. The accessibility of this coherent cell group make it amenable for studying protease/inhibitor roles in migratory processes.
Affigel blue beads were used to deliver a serine protease inhibitor, protease nexin-1 (PN-1), and a target protease, trypsin, to the olfactory epithelium coincident with initiation of GnRH neuronal migration. PN-1 inhibited neuronal migration while trypsin accelerated their transit into the CNS. Prior to initiation of migration, neither PN-1 nor trypsin altered the timing of neuronal exit. Trypsin did, however, accelerate the timing of neuronal crossing into the nerve-forebrain junction.
These data support the hypothesis that protease activity modulates neuronal movements across barriers. Moreover, the data suggest, for the first time, that aspects of GnRH neuronal migration may be cell autonomous but modulated by ECM alterations.
A key component regulating neuronal migration is the appropriate spatio-temporal expression of extracellular matrix (ECM) molecules which contribute to the highway along which neurons travel. Proteins, such as serine proteases and their inhibitors, could alter the quality of this highway and thus play critical roles in migratory processes . Members of the serine protease inhibitor superfamily, or serpins, act by binding to and permanently inactivating their target protease(s). One member of this family, protease nexin-1 (PN-1), was first described by Monard et al.. Though initially characterized for its ability to stimulate neurite outgrowth [2–5], PN-1 also modulates neuronal migration as exemplified by Lindner et al.. Their studies demonstrate that PN-1 slows granule cell movement from the external to internal layers in postnatal mouse cerebellar slice cultures.
Interestingly, this inhibition of migration by protease inhibitors may be balanced by the stimulation of migration via proteases. For example in vitro addition of plasmin, a serine protease, accelerates the migration of neuroblastoma cells through a matrigel base by a factor of five . The subsequent addition of aprotinin, a plasmin inhibitor, decreases the migratory population to the same degree [8, 9]. Furthermore, Seeds et al. demonstrated a retardation of granule cell migration in tissue plasminogen activator (tPA) knock-out mice. These data support the hypothesis that a balance exists between serine proteases and their inhibitors such that changes in this balance delay or promote neuronal migration. The present study was initiated to test this hypothesis in vivo by examining neuronal migration of chick gonadotropin releasing hormone (GnRH) neurons during embryogenesis. The site of origin of these cells in the olfactory placode, as well as the time course and migratory route along the olfactory nerve (ON) and into the forebrain are well documented [11–14]. Previous work in the laboratory has shown that olfactory axons emerge from the olfactory epithelium at stage 18 and are first joined by glia  and GnRH neurons  at stage 21.
In order to test whether proteolysis or its inhibition affect GnRH cellular migration, we performed experiments at two critical developmental time points. In both of these a protease or its inhibitor was applied by placing protein-coated beads at the olfactory placode. The first experiments tested whether application of either of these agents over the period of stage 21 to stage 29 affected the initial exit of GnRH neurons from the OE and/or their rate of migration along the ON and into the CNS. The second experiments tested whether GnRH neurons exited the OE irrespective of the effects of proteolysis on the maturation of the olfactory nerve. In this case protein-soaked beads were applied prior to GnRH exit (stage 17) and the effects were tested at succeeding stages up to and including their normal exit time (stages 18, 19, 20, 21). In the latter experiments the effects of proteolysis and its inhibition on the development of the olfactory nerve itself were tested using axonal, glial and neuronal outgrowth markers. These are the first experiments to demonstrate the critical roles of proteolysis and its inhibition on the regulation of GnRH cellular migration.
PN-1 and trypsin modulate GnRH neuronal migration in vivo during embryogenesis
All embryos analyzed were stage 21 at the time of bead implantation and stage 29 at the time of fixation. In control embryos (n = 10) receiving a PB coated bead, GnRH neurons in each compartment were counted on the side ipsilateral and contralateral to the bead. There was no effect of the bead on GnRH neuronal distribution (Table 1) or total number (Table 2). Sections counterstained with cresyl violet revealed no morphological abnormalities of the epithelium caused by insertion of the bead (Figure 1).
In PN-1 treated embryos, the distribution of GnRH neurons within the olfactory epithelium, nerve and brain on the side contralateral to the bead and that of controls were not significantly different indicating that the contralateral side in experimental embryos served as an internal control. Therefore, statistical analysis was performed comparing values within embryos (i.e. GnRH neuronal distribution ipsilateral to the bead was compared to that contralateral to the bead). Significantly more neurons remained within the epithelium (P < 0.03) and fewer had crossed into the brain (P < 0.002, see Table 1) on the PN-1 treated side. The effects of PN-1 on GnRH neuronal distribution cannot be attributed to changes in total cell number as there was no difference in this parameter between groups (Table 2).
Other serine protease inhibitors tested included: soybean trypsin inhibitor and Type IV chicken ovoinhibitor (data not shown). These protease inhibitors demonstrated a range of effects on the distribution of GnRH neurons across the three compartments. Both concentrations of soybean trypsin inhibitor tested (1 mg/ml, n = 6 and 10 mg/ml, n = 4) had no significant effect on the distribution of GnRH neurons. Application of type IV chicken ovoinhibitor led to a decrease in the percent of GnRH neurons remaining in the OE (P < 0.02) and a larger percent within the telencephalon (P < 0.03).
PN-1 has four known target proteases: urokinase plasminogen activator (uPA), tissue type plasminogen activator (tPA), thrombin and trypsin . Evidence exists for a role of both trypsin [18, 19] and uPA [20, 21] in migratory processes. Therefore, both were tested in our system. All comparisons made were of the treated side (ipsilateral to the bead) and the untreated side (contralateral to the bead).
Trypsin resulted in fewer GnRH neurons within the epithelium (P < 0.008) and along the olfactory nerve (P < 0.04) and more within the brain (P < 0.0001, see Table 1). There was no significant difference in the total number of GnRH neurons (Table 2) compared to control. The effect of trypsin is specific since in embryos receiving a uPA bead, there was no effect of the protease on the distribution of GnRH neurons (data not shown).
GnRH neuronal migration is cell autonomous but modulated by composition of the ECM
As PN-1 can stimulate neurite outgrowth, [2–5] we tested its effects on outgrowth and maturation of the olfactory nerve. Maturation of the nerve was followed by immunoreactivity to axonal, glial and neuronal markers (summarized in Table 3). All embryos analyzed were stage 17 at the time of bead implantation and stages 18–21 at the time of fixation.
Unilateral insertion of PB coated beads into the olfactory placode of stage 17 embryos did not disrupt the development of either axonal or glial components of the olfactory nerve between stages 18–21 (Table 3). The time of axonal outgrowth and sequential acquisition of axonal and glial markers were identical to that observed previously . The porous nature of the bead was compatible with axonal elongation through the mesenchyme towards the developing telencephalic vesicle. In fact, immunoreactive axons were found coursing through the bead (Figure 2). Likewise, there was no alteration in the timing of GnRH neuronal migration out of the epithelium. At stage 21, GnRH neurons were found within the olfactory epithelium and along the olfactory nerve (Table 3), a distribution appropriate for this stage.
Implantation of PN-1 beads did not stimulate premature olfactory nerve axogenesis. As in controls, very few MAP1b immunoreactive neurites were present at stage 18 (Table 3). However, PN-1 application did accelerate the biochemical differentiation of the axons. For instance, under normal conditions, olfactory axons acquire immunoreactivity to NCAM at stage 20. In PN-1 treated embryos, NCAM immunoreactivity was instead present at stage 19. The sequence of appearance of all markers, however, remained identical to controls. As the length of each developmental stage varies , it is difficult to determine precisely the amount of time by which biochemical development of the axons is accelerated. On average, however, biochemical differentiation is advanced by 7 hours. Just as PN-1 did not alter the timing of axogenesis, it also had no effect on the timing of glial entry into the nerve (stage 21). Under these conditions, that is, accelerated biochemical differentiation of olfactory axons, GnRH neuronal distribution was not altered. GnRH neurons were found within the epithelium and along the nerve and, most importantly, none had crossed into the brain.
Implantation of trypsin coated beads at stage 17 had no effect on either the timing of nerve development (axonal or glial) or the biochemical differentiation of the axons. The distribution of GnRH neurons, however, was altered (Table 3). Under normal conditions, large numbers of GnRH neurons are within the telencephalon by approximately stage 25. In the presence of trypsin, however, GnRH neurons crossed the nerve/brain junction at stage 21, representing a significant acceleration of this event. Even more significantly, these cells had continued along their normal migratory path into the presumptive septal and preoptic areas, their normal target sites.
Application of uPA beads at stage 17 had no effect on axonogenesis or the nerve's biochemical differentiation or glial ensheathment. The distribution of GnRH neurons was likewise not altered (data not shown).
PN-1 and trypsin expression along the GnRH migratory route
Endogenous trypsin immunoreactivity was present in the vast majority of cells within the head of the chick during the time period studied (stage 21–29). These cells included those within the olfactory epithelium and throughout the mesenchyme as well as axonal tracts within the developing face, including the olfactory nerve (figure 3, panel A). To ensure that the immunoreactivity we see in chick is specific, trypsin protein was pre-adsorbed with the anti-trypsin antibody. This complex was then used to immunostain chick sections (stages 21–23). No immunoreactivity was evident suggesting that the staining pattern seen in the chick using the anti-trypsin antibody was specific (figure 3, panel B). Unlike trypsin, no immunoreactive uPA was present within regions of the olfactory system or the developing telencephalic vesicle during this time frame (data not shown).
Antibodies that recognize chick PN-1 are not available and thus this protease inhibitor was localized using mouse embryonic tissue at developmental times corresponding to the chick stages 21–29. Double confocal immunofluoresence of mouse tissue (embryonic day 15, El 5) demonstrated that MAP1b immunoreactive axons of the vomeronasal nerve (VNN), the highway for GnRH neurons in the mouse [11, 13] express PN-1 protein (Figure 4) but not trypsin (data not shown). Importantly, PN-1 immunoreactivity was not limited to MAP1b immunoreactive axons, but was also present within the basal laminae of the vomeronasal organ (VNO) as well as within the adjacent mesenchyme (Figure 4). In both El 5 and adult mouse brains, PN-1 immunoreactivity within the olfactory bulb was diffuse but appeared to be more concentrated within the glomerular layer (data not shown). S100 positive glia of the VNN express trypsin (Figure 5) within the cell bodies and along major processes; the diffuse staining suggested it was also in the matrix of the VNN (Figure 5, 5B). It is clear that PN-1 protein was not present in the same structures as those immunoreactive for trypsin (Figure 6) or GnRH (data not shown).
This is the first report in which the in vivo application of a serine protease or its inhibitor have been demonstrated to affect embryonic neuronal migration. Our data demonstrate stage specific effects of PN-1 and trypsin on the distribution of chick GnRH neurons along their migratory route, without an alteration of their total population.
Stage specific introduction of these proteins was via unilateral insertion (into either the olfactory epithelium or placode) of protein coated Affigel Blue beads. The use of these beads is an established method widely utilized to deliver exogenous proteins during development. For example, in their study of limb development, Fallon et al. demonstrated depletion of iodinated FGF protein from Affigel Blue beads indicating protein does indeed diffuse out of the bead. In fact, the authors demonstrated that approximately half the iodinated protein diffused off the bead within the first 24 hours and 70% diffused by approximately 60 hours. These data indicate that protein is present and diffusing into the surrounding area up to 60 hours following implantation of the bead. Our experiments were carried out within this window of time (there are 24 hours between stage 17 to 21 and 60 hours between stage 21 and 29). In addition, subsequent studies examining the roles of BMP, FGF's and Shh have also utilized Affigel Blue beads to exogenously introduce various protein components [24, 25]. The results of these studies have been consistent with the known temporal and spatial distributions of these proteins.
Modification of the extracellular milieu via local shifts in the protease/inhibitor balance may regulate neuronal migration. This hypothesis is supported by our findings on stage 21–29 embryos. In these experiments, inhibition of endogenous trypsin-like activity by PN-1 resulted in fewer GnRH neurons exiting the olfactory epithelium and a corresponding decrease in the number entering the brain. Conversely, increasing trypsin availability promoted neuronal crossing of these two boundary zones. We hypothesize that the serine protease/inhibitor pair act by altering the ECM through which GnRH neurons migrate. Matrix involvement in migration is supported by the identification of matrix components throughout the GnRH migratory route. At the epithelium, GnRH neurons cross the basal laminae to initiate their migratory phase . The olfactory nerve expresses several matrix molecules [heparan and keratan sulfate proteoglycans , laminin , phosphocan , lectin-binding domains ]. Any or all of these may serve as substrates for proteolysis. The three domains, the olfactory epithelium, olfactory nerve and the brain, represent regulatory road blocks to the GnRH cell. By inhibiting local proteolysis, PN-1 produces a non-conducive environment at these points. Likewise, promotion of local proteolysis by trypsin, results in a permissive migratory environment.
Though modification of the ECM composition may indeed explain the data, another explanation may lie in the activation/inhibition of protease activated receptors (PAR's). These two hypotheses are not mutually exclusive but rather may work in concert to regulate neuronal migration. PAR'S are G-coupled receptors activated by proteolytic cleavage of their exo-domains. This cleavage exposes an amino acid sequence which then serves as a tethered ligand activating transmembrane signaling. Four PAR'S have been identified (PAR 1–4); PAR'S 1,3 and 4 are activated by thrombin while PAR2 is activated by trypsin . Activation of PAR'S may alter ECM composition. For example, Hattori et al. demonstrated that thrombin activation of PAR1 led to deposition of P-selectin, a leukocyte adhesion molecule, on the surfaces of endothelial cells. This change in matrix composition allows for leukocyte attachment and subsequent infiltration of the endothelium. PAR'S are expressed in the developing rat CNS  as well as in the embryonic chick . Though we did not localize PAR expression in our model system, it remains a possibility that their activation or inhibition may modulate the ECM composition and thus GnRH neuronal migration.
The fact that mammalian PN-1 alters neuronal migration in an avian species suggests the presence of endogenous serine protease activity in the region. Such a protease, with trypsin-like immunoreactivity, was detected by immunocytochemistry. To biochemically characterize this endogenous activity, non-neurally derived trypsin inhibitors were tested. At the concentrations tested, soybean trypsin inhibitor had no effect on GnRH migration. These results could be due to differences in binding affinity between soybean trypsin inhibitor and PN-1 for the endogenous trypsin-like molecule. The inhibition of trypsin-like proteases by different inhibitors (including PN-1 and soybean trypsin inhibitor) varies widely and a lack of an effect is not uncommon (e.g. 34).
Contrary to the effect seen with PN-1, type IV chick ovoinhibitor accelerated neuronal migration with fewer GnRH neurons in the epithelium and correspondingly more within the brain. At least two mechanisms can explain this result. First, type IV chick ovoinhibitor may not be acting as an inhibitor in our system as it has been demonstrated to be ineffective in other systems [34–36]. Alternatively, if it is serving as a protease inhibitor, it may inactivate a molecule different from that affected by PN-1 and, in doing so, generate an environment permissive for neuronal migration.
Both non-neuronally derived trypsin inhibitors tested yielded results different from that of PN-1 suggesting they possess different protease specificities, affinities, or functions. Regardless of their mechanisms of action, these data support the hypothesis that changes in enzymatic activities can influence neuronal migration.
In contrast to PN-1, trypsin leads to a permissive environment during this developmental period (stages 21–29) resulting in a global acceleration of GnRH neuronal migration out of the olfactory epithelium and into the brain. Trypsin cleaves peptide bonds at the carboxyl side of either arginine or lysine residues. This rather non-specific cleavage suggests trypsin may alter many different components of the ECM which themselves vary in each compartment. Interestingly, in the chick, trypsin immunoreactivity was present throughout the head as well as in the olfactory nerve. This ubiquitous distribution suggests that the specificity of the protease/inhibitor system may be imparted by an avian equivalent of PN-1.
We found no effect on GnRH neuronal distribution in uPA-treated embryos and no uPA immunoreactivity. This result is not surprising in light of a study by Del Bigio et al. in which the expression pattern of uPA was analyzed in the postnatal mouse. Based on its spatio-temporal expression pattern, the authors concluded that uPA may function in processes of synaptogenesis and remodeling rather than in cell migration. In addition, our data indicate that simply coating beads with any serine protease is not sufficient to influence migration. Thus, not only is our experimental approach unbiased, but the antagonistic relationship of PN-1 and trypsin on GnRH neuronal migration is specific.
A PN-1 specific antibody that cross reacts with chick tissue is not available, thus we were unable to follow its expression in the chick. Although avian and mammalian serpins are members of the same superfamily, they are evolutionarily distinct . This divergence likely accounts for the species specificity of the PN-1 antibody. To determine whether PN-1 is expressed by the olfactory system during the time of active GnRH neuronal migration, we examined its expression in the embryonic mouse where its mRNA is known to be expressed . At E15, PN-1 protein is present within MAP1b immunoreactive axons of the vomeronasal nerve (the migratory path used by GnRH neurons in mammals). PN-1 immunoreactivity was also present within the basal laminae of the vomeronasal organ, a barrier crossed by GnRH neurons when they initiate their migration. This staining pattern, along with our data on PN-1's effect on migration, strengthens our hypothesis that this serine protease inhibitor plays a role in neuronal migration. In addition, expression of other serine protease inhibitors has been described in other migrating neurons. For example, Krueger et al. demonstrated increased expression of neuroserpin within migrating granule cells of the cerebellum in the post natal mouse.
In the mouse, trypsin immunoreactivity is present within S 100 immunoreactive glia which ensheath axons of the vomeronasal nerve. As with PN-1, it is also present in the extracellular matrix where it is likely that the protease/inhibitor pair function to regulate, at least in part, the environment through which GnRH neurons migrate.
Due to its ability to stimulate neurite outgrowth, we asked whether PN-1 could alter the timing of formation of the olfactory nerve and if so, what effect this might have on GnRH neuronal migration. For these experiments, bead implantation into the olfactory placode was performed at stage 17 just prior to olfactory nerve axonogenesis. PN-1 did not accelerate neurite outgrowth but did accelerate detectable levels of biochemical differentiation markers of the olfactory nerve. These data suggest that the olfactory neurons can respond to PN-1 directly or to changes in the local environment caused by PN-1.
The distribution of GnRH neurons was not altered by PN-1 at stages 17–21 in spite of the accelerated maturation of the olfactory nerve. Likewise, PN-1 did not alter the timing of the nerve's ensheathment by glia. This suggests that glial migration is independent of any matrix changes induced by PN-1. The fact that GnRH neurons and the glial ensheathing cells exit at the same time (stage 21) may be coincidental or may be due to an interaction between these two populations. Alternatively, the timing of exit of GnRH neurons and glia may be cell-autonomous events.
Implantation of a trypsin bead at stage 17 had no effect on the biochemical maturation of the olfactory nerve nor on the timing of glial or GnRH neuronal migration. At this early stage, at least some of the barriers to GnRH neuronal exit from the epithelium are in place . Therefore, the lack of an effect on migration by trypsin suggests that the initiation of migration is an inherent property of the GnRH neuron (and glial cell). At stage 21, however, trypsin did significantly alter the distribution of GnRH neurons such that a large population was already in the brain. These neurons not only entered the brain early but also traveled caudalward within the brain along their normal arching trajectory.
Taken together, these data suggest that in the presence of either trypsin or PN-1 (at stage 17), GnRH neurons exit the olfactory epithelium at stage 21, as in controls. Therefore, the ability to initiate migration resides within the neuron itself such that alterations of ECM composition during this time (stage 17–21) are irrelevant to the timing of this initial event. The finding that the neurons enter the CNS early in trypsin-treated embryos suggests that continued movement may be a cell autonomous event with trypsin-induced proteolysis generating a permissive environment. Finally, these data demonstrate that the GnRH neuron's ability to transit across the glia limitans and through the brain to its target sites is independent of additional maturation of the neuron itself, the olfactory nerve or the brain.
Our data support a role of proteases and their inhibitors in neuronal migration. The complex interactions between a neuron and its environment are likely not regulated by proteolysis alone. The characteristic directed migratory pattern taken by the GnRH neuron and the cohesiveness of the population suggests a more complex system is in place to ensure their appropriate translocation into the brain. In fact, Kramer and Wray  have identified a novel gene, nasal embryonic LHRH (GnRH) factor or NELF, which is expressed by GnRH neurons during their migratory phase and olfactory sensory neurons as they initiate axonogenesis. Antisense depletion of NELF led to a decrease in both olfactory axonal outgrowth and the number of GnRH neurons exiting the epithelium. The authors suggest that NEFL may function as a migratory factor. It seems likely therefore that several components interact to orchestrate the proper migration of neurons.
Materials and Methods
Animal and tissue preparation
Fertilized eggs (white leghorn, SPAFAS, Preston, CT) were placed in an incubator (Humidaire Incubator, Co. New Madison, OH) at 99.5°C and 85% relative humidity. A window was cut in each shell to determine the developmental stage of each embryo . To visualize the extraembryonic membranes, Fast Green (1:10,000 Molecular Probes, Eugene, OR) was applied to the surface of the embryo and membranes were teased apart using forceps. Appropriately sized Affigel Blue beads (BioRad, Hercules, CA) were unilaterally inserted either into the olfactory placode (stage 17) or the olfactory epithelium (stage 21) and the egg was returned to the incubator until time of fixation. Control animals were implanted with beads coated with 0.1 M phosphate buffer, pH 7.3 (PB, N = 10). Experimental embryos were implanted with beads coated with PN-1 bead (N = 12) or trypsin (N = 11). Embryos receiving a bead at stage 17 were fixed at stage 18 (N = 9), stage 19 (N = 16), stage 20 (N = 17) or stage 21 (N = 9). Embryos receiving a bead at stage 21, were fixed at stage 29 (N = 10).
Embryos were fixed by immersion in 4% paraformaldehyde (Fisher Scientific, Pittsburgh, PA) for 1–7 days depending on the stage (younger embryos required shorter fixation times). Fixed embryos were embedded in 8% gelatin and fixed in 4% paraformaldehyde. 100 μm sagittal sections were cut on a vibratome (DSK Microslicer 1500E, Ted Pella, Inc., Redding, CA) and immunocytochemistry was performed on free-floating sections. Tissue was then mounted onto slides, dehydrated through graded alcohols, cleared with HemoD (Fisher) and coverslipped with Permount (Fisher).
As reagents for the localization of PN-1 in the chick are not available, we examined its localization in the embryonic mouse at the time of GnRH migration. Immunolocalization of PN-1 protein was performed on embryonic day 15 (El 5, day of plug was considered E0.5). Swiss Webster mice were used (Charles River, Kingston, MA). Mouse embryos (N = 6) and an adult female (N = 1) were processed for double label immunofluorescence to determine the cellular localization of PN-1 and trypsin. The mothers were euthenized with CO2 and embryos placed in PB and decapitated rapidly. The adult was anesthetized with nembutal (70 mg/kg) and perfused transcardially. Tissue was treated as described above.
Anesthesia, Surgery, and Perfusion
All procedures for the mice met with NIH guidelines and were approved by the Institutional Animal Care and Use Committee of Columbia University.
Affigel-Blue bead preparation
Affigel Blue beads (BioRad, Hercules, CA) were sized using a dissecting microscope and forceps as described by Vogel et al.. Beads 30–50 μm in diameter were used for stage 21 embryos and beads 20 μm in diameter were used for stage 17 embryos to accommodate the smaller target area. Beads were placed in one of the following solutions: 3.1 mg/ml of recombinant rat PN-1; 2.3 mg/ml of trypsin (type III bovine pancreas, Sigma, St. Louis, MO); 1 mg/ml urokinase plasminogen activator (uPA, Sigma, St Louis, MO); 1 or 10 mg/ml soybean trypsin inhibitor (Sigma, St Louis, MO); 10 mg/ml type IV chick egg white purified ovoinhibitor (Sigma, St Louis, MO) at 4°C overnight and used the next day. Control beads were soaked in PB overnight at 4°C and used the next day.
Free floating immunocytochemistry
Tissue was washed and treated with 0.5% hydrogen peroxide to remove endogenous peroxidase activity. Following an overnight incubation in 0.1% Triton X-100 (Tx100, Sigma, St Louis, MO) containing 3% normal goat serum in PB at 4°C, sections were incubated in rabbit polyclonal anti-GnRH antibody (SW-1, 1:5000 in 0.1% Tx100 in PB, generously provided by Dr. S. Wray, NIH) for at least 4 days at 4°C. Following three PB washes, tissue was then incubated in biotinylated goat-anti-rabbit-IgG (1:200, Vector Labs, Burlingame, CA) in 0.1% Tx100 in PB overnight at 4°C. The following day, sections were washed in PB and incubated in avidin-biotin-HRP complex (1:200, Vector Labs, Burlingane, CA) for at least 3 hours at room temperature. After PB washes, bound antibody was detected using 3,3'-diaminobenzidine (DAB, Sigma, St Louis, MO) as the chromogen.
Brains processed for immunocytochemical localization of protease, PN-1 or axonal/glial markers were treated as described above, however the primary antibodies used were specific for each protein (see list below). Sections were viewed and photographed with an Olympus Vanox microscope (New York/New Jersey Scientific Inc., Middlebush, NJ).
Brains processed for double label immunofluorescence were treated as described above. The first antibody was detected using the appropriate biotinylated IgG followed by avidin-fluorophore (either Texas Red or FITC, Sigma, St Louis, MO), while the second antibody was detected by a directly conjugated IgG-fluorphore. All fluorescent images were acquired with a Zeiss confocal microscope using LSM 410. Images were acquired at 40 or 100X using 16 averaged scans at 1028 × 1028 pixel resolution and printed using Adobe Photoshop IV.
To test the specificity of the method, tissue was processed as described above for the first antibody. In the second set of reactions, 3% normal mouse serum (Vector Labs, Burlingane, CA) in 0.1% Tx100 in PB was substituted for the primary antibody. This was followed by horse anti-mouse IgG-FITC. Under these conditions, no FITC immunofluorescence was detected. As an additional control for trypsin immunoreactivity in the CNS, trypsin protein was incubated with the anti-trypsin antibody for 4 hours at 4°C for antibody adsorption. This antigen/antibody complex was then utilized to immunostain chick tissue sections; no immunoreactivity was detected (see figure 3).
Antibodies/antisera and dilutions
NCAM: A mouse monoclonal antibody raised against the highly sialylated embryonic forms of the neural cell adhesion molecule was used (1:1, Developmental Studies Hybridoma Bank).
NF: Two mouse monoclonal antibodies raised against the heavy (200 kD) and light (68 kD) forms of neurofilament were used (1:200 each, Sigma, St Louis, MO). Both antibodies recognize phosphorylated variants of neurofilament.
MAP1b: A mouse monoclonal antibody to the microtubule associated protein 1b was generously provided by Dr. Lester Binder, University of Alabama at Birmingham. The antibody was used at 1:1000 and was selected because MAP1b is the earliest expressed MAP both in vivo and in vitro.
PGP9.5: A rabbit polyclonal antibody raised against human protein gene product 9.5 was used at 1:1000 (Biogenesis, Ltd,. Poole, England). This is a neuron-specific ubiquitin carboxy terminal hydrolase.
P 0 : A mouse monoclonal antibody, 1E8, raised against the mammalian myelin protein, P0, was used at 1:4000 and was generously provided by Dr. R. Brackenbury (University of Cincinnati, Cincinnati, OH). This antibody recognizes Schwann and ensheathing cells of the olfactory nerve but not astrocytes.
MAP4: A mouse monoclonal antibody raised against microtubule associated protein 4, MAP4, was generously provided by Dr. Chloe Bulinski (Columbia University, NY, NY) and used at 1:1000. MAP4 is the major MAP expressed by non-neuronal tissue.
S100: A rabbit polyclonal anti-S100 antibody was used at 1:1000 (Biogenesis, Ltd, Poole, England). S 100 is a central and peripheral glial cell marker.
GnRH: a polyclonal antibody raised against GnRH conjugated with glutaraldehyde to ovalbumin was generously provided by Dr. Susan Wray (NIH). This antibody recognizes amino acids: 3,4,7,8,9, and 10 of the GnRH peptide and was used at 1:5000.
Trypsin: An anti-human cationic trypsin antibody was used at 1:1000 (Biodesign, Kennebunk, ME).
uPA: An anti-uPA antibody was used at 1:1000 (Accurate Chemical, Westbury, NY).
Protease inhibitor antibody
PN-1: An anti-rat PN-1 antibody was used at 1:500 and was generously provided by Dr. D. Monard (Friedrich Miescher Institut, Basel, Switzerland).
To ensure that the proteases and inhibitors used were active, a coagulation assay was performed. Blood alone (from PD) coagulated in approximately 2 minutes. Incubation of blood with 1 mg/ml uPA delayed coagulation significantly (by several minutes). Incubation with combined PN-1 and uPA resulted in rapid coagulation as in control.
Cell counts and statistical analysis
Cell counts for PN-1 and serine proteases were performed by PD who was unaware of the experimental status of the embryos. Those for the other serine protease inhibitors were carried out by a second observer (XLZ). Both observers carried out independent counts on separately prepared sets of PB controls. An equal number of immunoreactive tissue sections was counted for each side of the face (i.e. the side containing the bead and the contralateral side). Selected sections were recounted by AJS to check for accuracy. Cell number was determined via a modified optical dissector method [44–46]. Examination of tissue reveals three focal planes; the nucleus being in crisp focus in only one of these planes. This profile allows cells (nuclei) to be counted in each of the three planes. Double counting is avoided for those cells in the top and bottom planes by counting alternate sections.
Immunoreactive GnRH neurons separated into categories depending on location: olfactory epithelium (OE), olfactory nerve (ON) and telencephalon (CNS). Numbers in each category were then expressed as a percent of total number of GnRH neurons on that side of the face. The contralateral side served as a within animal control. To analyze for significant differences in percentage of GnRH neurons in each category, an unpaired students t-test (p < 0.05) was performed.
Patterson PH: On the role of proteases, their inhibitors and the extracellular matrix in promoting neurite outgrowth. Journal of Physiology Paris. 1985, 80: 207-211.
Monard D, Solomon F, Rentsch M, Gysin R: Glial-induced morphological differentiation in neuroblastoma cells. PNAS. 1973, 70: 1894-1897.
Monard D, Niday E, Limat A, Solomon F: Inhibition of protease activity can lead to neurite extension in neuroblastoma cells. Progress in Brain Research. 1983, 58: 359-364.
Zurn AD, Nick H, Monard D: Glial derived nexin promotes neurite outgrowth in cultured chick sympathetic neurons. Developmental Neuroscience. 1988, 10: 17-24.
Farmer L, Sommer J, Monard D: Glial derived nexin promotes neurite extension in hippocampal pyramidal cells in vitro. Developmental Neuroscience. 1990, 12: 73-80.
Lindner J, Guenther J, Nick H, Zinser G, Antonicek H, Schachner M, Monard D: Modulation of granule cell migration by glial derived protein. PNAS. 1986, 83: 4568-4571.
Shea TB, Beermann ML: Regulation of neuronal migration and neuritogenesis by distinct surface proteases: relative contribution of plasmin and a thrombin-like protease. FEES. 1992, 307: 190-194. 10.1016/0014-5793(92)80765-9.
Seeds NW: Molecular Aspects of Development and Aging of the Nervous System. Edited by: JM Lauder. 1990, 169-178.
Seeds NW, Varrall S, Friedman G, Hayden S, Gadotti D, Haffke S, Christensen K, Gardner B, McGuire P, Krystoksek A: Plasminogen activators and plasminogen activator inhibitors in neural development. Annals of NY Academy of Science. 1992, 667: 32-40.
Seeds NW, Basham ME, Haffke SP: Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. PNAS. 1999, 96: 14118-14123. 10.1073/pnas.96.24.14118.
Schwanzel-Fukuda M, Pfaff D: Origin of leutinizing hormone releasing hormone neurons. Nature. 1989, 338: 161-164. 10.1038/338161a0.
Norgren RB, Lehman MN: Neurons that migrate from the olfactory epithelium in the chick express luteinizing hormone releasing hormone. Endocrinology. 1990, 128: 1676-1678.
Wray S, Nieburgs A, Elkabes S: Spatiotemporal cell expression of luteinizing hormone releasing hormone in the prenatal mouse: evidence of an embryonic origin in the olfactory placode. Developmental Brain Research. 1989, 46: 309-318. 10.1016/0165-3806(89)90295-2.
Silverman AJ, Livne I, Witkin JW: The gonadotropin releasing hormone (GnRH) neuronal systems: immunocytochemistry and in situ hybridization. The Physiology of Reproduction. Edited by: Knobil E, Neill JD. 1994, New Yrok: Raven Press, 1683-1710.
Drapkin PT, Silverman AJ: Development of the Chick Olfactory Nerve. Developmental Dynamics. 1999, 214: 349-360. 10.1002/(SICI)1097-0177(199904)214:4<349::AID-AJA7>3.3.CO;2-5.
Mulrenin EM, Witkin JW, Silverman AJ: Embryonic development of the gonadotropin releasing hormone (GnRH) system in the chick: a spatio-temporal analysis of GnRH neuronal generation, site of origin and migration. Endocrinology. 1999, 140: 422-433.
Monard D: Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. Trends in Neuroscience. 1988, 11: 541-544. 10.1016/0166-2236(88)90182-8.
Steven FS, Williams H, Maier J, Arndt J, Weidauer H, Born A: Status of trypsin-like enzymes in squamous cell carcinomas of the head and neck region. Journal of Cancer Research and Clinical Oncology. 1990, 116: 57-64.
Ford WL, Allen TD, Pitt MA, Smith ME, Stoddart RW: The migration of lymphocytes acress specialized vascular endothelium. II. The contrasting consequences of treating lymphocytes with trypsin and neuraminidase. Cell Tissue Kinetics. 1976, 9: 351-361.
Testa JE, Quigley JP: The role of urokinase plasminogen activator in aggressive tumor behavior. Cancer and Metastasis Reviews. 1990, 9: 353-367.
Quax PHA, deBart AC, Schalken JA, Verheijen JHL: Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. The Prostate. 1997, 32: 196-204. 10.1002/(SICI)1097-0045(19970801)32:3<196::AID-PROS6>3.0.CO;2-J.
Hamilton HL, Hamburger V: A series of normal stages in the development of the chick embryo. Journal of Morphology. 1951, 88: 49-92.
Fallon JF, Lopez A, Ros MA, Olwin BB, Simandl BK: FGF-2: Apical ectodermal ridge growth stimulated in chick limb development. Science. 1994, 264: 104-107.
Dealy CN, Scranton V, Cheng HC: Roles of transforming growth factor-alpha and epidermal growth factor in chick limb development. Developmental Biology. 1998, 202: 43-55. 10.1006/dbio.1998.8988.
Patel K, Makarenkova H, Jung HS: The role of long range, local and direct signalling molecules during chick feather bud development involving the BMPs, follistatin and the eph receptor tyrosine kinase eph-A4. Mechanisms of Development. 1999, 86: 51-62. 10.1016/S0925-4773(99)00107-0.
Nishizuka M, Aria S: Glycosaminoglycans in the olfactory epithelium and nerve of chick embryos: an immunocytochemical study. Neuroscience Research. 1996, 24: 165-173. 10.1016/0168-0102(95)00990-6.
Calof AL, Lander AD: Relationship between neuronal migration and cell-substratum adhesion: laminin and merosin promote olfactory neuronal migration but are anti-adhesive. Journal of Cell Biology. 1991, 115: 779-794.
Nishizuka M, Ikeda S, Arai Y, Maeda N, Noda M: Cell surface associated extracellular distribution of neural proteoglycan, 6B4 proteoglycan/phosphocan, in the olfactory epithelium, olfactory nerve, and cells migrating along the olfactory nerve in chick embryos. Neuroscience Research. 1996, 24: 345-355. 10.1016/0168-0102(95)01010-6.
Croucher SJ, Tickle C: Characterization of epithelial domains in the nasal passages of chick embryos: spatial and temporal mapping of a range of extracellular matrix and cell surface molecules during development of the nasal placode. Development. 1989, 106: 493-509.
Coughlin SR: How the protease thrombin talks to cells. PNAS. 1999, 96: 11023-7. 10.1073/pnas.96.20.11023.
Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ: Journal of Biological Chemistry. 1989, 264: 7768-7771.
Niclou SP, Suidan HS, Pavlik A, Vejsada R, Monard D: Changes in the expression of protease activated receptor 1 and protease nexin-1 mRNA during rat nervous system development and after nerve lesion. European Journal of Neuroscience. 1998, 10: 1590-1607. 10.1046/j.1460-9568.1998.00183.x.
Turgeon VL, Milligan CE, Houenou LJ: Activation of the protease-activated thrombin receptor (PAR)-1 induces motoneuron degeneration in the developing avian embryo. Journal of Neuropathology and Experimental Neurology. 1999, 58: 499-504.
Yamanishi R, Koter J, Fushiki T, Soneda T, Saitoh T, Oomori T, Satoh T, Sugimoto E: A specific binding of cholecystokinin-releasing peptide (monitor peptide) to the isolated rat small intestinal cells. Biochemical Journal. 1993, 166: 349-354.
Shahabuddin M, Criscio M, Kaslow DC: Unique specificity of in vitro inhibition of mosquito midgut trypsin-like activity correlates with in vivo inhibition of malaria parasite infectivity. Experimental Parasitology. 1995, 80: 212-219. 10.1006/expr.1995.1026.
Kikuno Y, Takahashi H, Suzuki T: Purification of prekallikrein from procine plasma and its conversion to active kallikrein. Journal of Biochemistry (Tokyo). 1983, 93: 235-241.
Del Bigio MR, Hosain S, Altumbabic M: Localization of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse forebrain during postnatal development. International Journal of Developmental Neuroscience. 1999, 17: 387-399. 10.1016/S0736-5748(99)00031-3.
Marshall CJ: Evolutionary relationships among the serpins. Philosophical Transcripts of the Royal Society Blon Biological Sciences. 1993, 342: 101-119.
Mansuy IM, van der Putten H, Schmid P, Meins M, Botteri FM, Monard D: Variable and multiple expression of protease nexin-1 during mouse organogenesis and nervous system development. Development. 1993, 119: 1119-1134.
Kreuger SR, Ghisu G-P, Cinelli P, Gschwend TP, Osterwalder T, Wolfer DP, Sonderegger P: Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. Journal of Neuroscience. 1997, 17: 8948-8990.
Vogel A, Roberts-Clarke D, Niswander L: Effect of FGF on gene expression in chick limb bud cells in vivo and in vitro. Developmental Biology. 1995, 171: 507-520. 10.1006/dbio.1995.1300.
Kramer PR, Wray S: Novel gene expressed in nasal region influences outgrowth of olfactory axons and migration of luteinizing hormone-releasing hormone (LHRH) neruons. Genes and Development. 2000, 14: 1824-1834.
Calvert R, Anderton BH: A microtubule associated protein (MAPI) which is expressed at elevated levels during development of the rat cerebellum. EMBO J. 1985, 4: 1171-1176.
Silverman AJ, Sutherland AK, Wilhelm M, Silver R: Mast cells migrate from blood to brain. Journal of Neuroscience. 2000, 20: 401-408.
West MJ, Slomianka L, Gundersen HJ: Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anatomical Record. 1991, 231: 482-479.
Coggeshall RE, Lekan HA: Methods for determining numbers of cells and synapses: a case for more uniform standards of review. Journal of Comparative Neurology. 1996, 364: 6-15. 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.3.CO;2-I.
Grant sponsor: NIH HD10665 (AJS), R01 NS 20335 (AJS), NIH 32T NS07062 (PTD). The confocal microscopy was established by NIH Shared Instrumentation Grant #1S10RR10506 and support by NIH Grant #P30 CA13696 as part of the Herbert Irving Cancer Center at Columbia University. We would like to thank Ms. Xinlan Zhou (XLZ in text) for her work on the non-neuronal protease inhibitors and Dr. Joan Witkin for critical readings of the manuscript.
Authors’ original submitted files for images
About this article
Cite this article
Drapkin, P.T., Monard, D. & Silverman, AJ. The role of Serine Proteases and Serine Protease Inhibitors in the migration of Gonadotropin-Releasing Hormone neurons. BMC Dev Biol 2, 1 (2002). https://doi.org/10.1186/1471-213X-2-1